Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
43.28 USD | -1.28% | +8.47% | +17.13% |
07/05 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
07/05 | Transcript : Halozyme Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.13% | 5.58B | |
+3.91% | 108B | |
+11.25% | 104B | |
+1.28% | 22.33B | |
-13.01% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-9.96% | 17.64B | |
+3.79% | 14.05B | |
+36.44% | 12.51B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Morgan Stanley Cuts Halozyme Therapeutics Price Target to $59 From $61, Maintains Overweight Rating